Drug intervention trials in sepsis: divergent results

被引：92

作者：

Polderman, KH ^{[1
]}

Girbes, ARJ ^{[1
]}

机构：

[1] Vrije Univ Amsterdam Med Ctr, Dept Intens Care, NL-1000 MB Amsterdam, Netherlands

来源：

LANCET | 2004年 / 363卷 / 9422期

关键词：

D O I：

10.1016/S0140-6736(04)16259-4

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

引用

收藏

页码：1721 / 1723

页数：3

相关论文

共 24 条

[1]

Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis -: A randomized controlled trial [J].

Abraham, E ;

Reinhart, K ;

Opal, S ;

Demeyer, I ;

Doig, C ;

Rodriguez, AL ;

Beale, R ;

Svoboda, P ;

Laterre, PF ;

Simon, S ;

Light, B ;

Spapen, H ;

Stone, J ;

Seibert, A ;

Peckelsen, C ;

De Deyne, C ;

Postier, R ;

Pettilä, V ;

Sprung, CL ;

Artigas, A ;

Percell, SR ;

Shu, V ;

Zwingelstein, C ;

Tobias, J ;

Poole, L ;

Stolzenbach, JC ;

Creasey, AA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02) :238-247

[2]

Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study [J].

Alberti, C ;

Brun-Buisson, C ;

Burchardi, H ;

Martin, C ;

Goodman, S ;

Artigas, A ;

Sicignano, A ;

Palazzo, M ;

Moreno, R ;

Boulmé, R ;

Lepage, E ;

Le Gall, JR .

INTENSIVE CARE MEDICINE, 2002, 28 (02) :108-121

[3]

Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care [J].

Angus, DC ;

Linde-Zwirble, WT ;

Lidicker, J ;

Clermont, G ;

Carcillo, J ;

Pinsky, MR .

CRITICAL CARE MEDICINE, 2001, 29 (07) :1303-1310

[4]

Unraveling severe sepsis - Why did OPTIMIST fail and what's next? [J].

Angus, DC ;

Crowther, MA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02) :256-258

[5]

Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].

Bernard, GR ;

Vincent, JL ;

Laterre, P ;

LaRosa, SP ;

Dhainaut, JF ;

Lopez-Rodriguez, A ;

Steingrub, JS ;

Garber, GE ;

Helterbrand, JD ;

Ely, EW ;

Fisher, CJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709

[6]

INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis [J].

Cohen, J ;

Carlet, J .

CRITICAL CARE MEDICINE, 1996, 24 (09) :1431-1440

[7]

Recombinant human activated protein C in sepsis: Inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials [J].

Eichacker, PQ ;

Natanson, C .

CRITICAL CARE MEDICINE, 2003, 31 (01) :S94-S96

[8]

Antithrombin III in patients with severe sepsis - A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis [J].

Eisele, B ;

Lamy, M ;

Thijs, LG ;

Keinecke, HO ;

Schuster, HP ;

Matthias, FR ;

Fourrier, F ;

Heinrichs, H ;

Delvos, U .

INTENSIVE CARE MEDICINE, 1998, 24 (07) :663-672

[9]

DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ANTITHROMBIN-III CONCENTRATES IN SEPTIC SHOCK WITH DISSEMINATED INTRAVASCULAR COAGULATION [J].

FOURRIER, F ;

CHOPIN, C ;

HUART, JJ ;

RUNGE, I ;

CARON, C ;

GOUDEMAND, J .

CHEST, 1993, 104 (03) :882-888

[10]

Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis [J].

Garnacho-Montero, J ;

Garcia-Garmendia, JL ;

Barrero-Almodovar, A ;

Jimenez-Jimenez, FJ ;

Perez-Paredes, C ;

Ortiz-Leyba, C .

CRITICAL CARE MEDICINE, 2003, 31 (12) :2742-2751